Access to the PDF text

Archives of cardiovascular diseases
Volume 106, n° 5
pages 333-339 (mai 2013)
Doi : 10.1016/j.acvd.2013.02.003
Received : 6 Mars 2012 ;  accepted : 14 February 2013
Drug-induced valvular heart disease: An update
Valvulopathies médicamenteuses. Mise au point

Figure 1

Figure 1 : 

Patient with toxic aortic and mitral valvulopathy due to benfluorex. On this apical four-chamber view using two-dimensional echocardiography, the mitral leaflets have lost their flexibility. Note the marked remodelling of the mitral subvalvular apparatus, with slight thickening of both leaflets.

Figure 2

Figure 2 : 

Same patient as in Fig. 1: the aortic cusps are slightly thickened, restrictive and fibrous-looking, with defective central coaptation.

Figure 3

Figure 3 : 

Mechanisms of drug-induced valvular heart disease. TGFβ: transforming growth factor beta.

EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline